Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

ABSTRACT:

Importance

Tests that predict outcomes for patients with acute myeloid leukemia (AML) are imprecise, especially for those with intermediate risk AML.

Objectives

To determine whether genomic approaches can provide novel prognostic information for adult patients with de novo AML.

Design, setting, and participants

Whole-genome or exome sequencing was performed on samples obtained at disease presentation from 71 patients with AML (mean age, 50.8 years) treated with standard induction chemotherapy at a single site starting in March 2002, with follow-up through January 2015. In addition, deep digital sequencing was performed on paired diagnosis and remission samples from 50 patients (including 32 with intermediate-risk AML), approximately 30 days after successful induction

SUBMITTER: Klco JM 

PROVIDER: S-EPMC4621257 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature